CMV-CTL for the Treatment of CMV Infection After HSCT
Cytomegalovirus Specific Cytotoxic T Lymphocyte for the Treatment of Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
A PHASE4 clinical study on Cytomegalovirus Infections and Hematological Disease, this trial is completed. The trial is conducted by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine and has accumulated 11 data snapshots since 2016. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
May 2023 — Jul 2024 [monthly]
Completed PHASE4
-
Apr 2023 — May 2023 [monthly]
Completed PHASE4
Status: Recruiting → Completed
-
Apr 2021 — Apr 2023 [monthly]
Recruiting PHASE4
▶ Show 6 earlier versions
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE4
-
May 2020 — Jan 2021 [monthly]
Recruiting PHASE4
-
Oct 2018 — May 2020 [monthly]
Recruiting PHASE4
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE4
-
May 2017 — Jun 2018 [monthly]
Recruiting PHASE4
-
Jan 2017 — May 2017 [monthly]
Recruiting PHASE4
First recorded
Nov 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
For direct contact, visit the study record on ClinicalTrials.gov .